Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine if intravitreal injections of ranibizumab decrease
the proportion of eyes in which vitrectomy is performed compared with saline injections in
eyes presenting with vitreous hemorrhage from proliferative diabetic retinopathy.